<div>
  <ul>
    <li>
      <p>
        California-based AI drug discovery startup Genesis Therapeutics has raised USD 200 million in a Series B funding round co-led by a US-based life sciences-focused investor (name undisclosed) and Andreessen Horowitz Bio + Health, with participation from other existing and new investors. This brings the total funds raised by the company to over USD 280 million.
      </p>
    </li>
    <li>
      <p>
        The funds will be used to further develop the company&rsquo;s AI-powered Genesis Exploration of Molecular Spaces (GEMS) platform, advance its pipeline of therapeutic candidates into clinical development, and further expand its pipeline with new programs.&nbsp;
      </p>
    </li>
  </ul>
  <p>
  </p>
</div>


<div>
  <p>
    <a href="https://www.businesswire.com/news/home/20230821419353/en/Genesis-Therapeutics-Closes-Oversubscribed-200-Million-Series-B">
      Press release 
    </a>
  </p>
  <p>
    <a href="https://www.pharmaceutical-technology.com/news/genesis-therapeutics-200m-series-b/?cf-view">
      Pharmaceutical Technology
    </a>
  </p>
</div>


All Updates

Genesis Therapeutics raises USD 200 million in Series B funding

Genesis Therapeutics and Eli Lilly team up on USD 670 million AI deal